Photocontrol of Antibacterial Activity: Shifting from UV to Red Light Activation

被引:241
作者
Wegener, Michael [1 ,4 ]
Hansen, Mickel J. [1 ]
Driessen, Arnold J. M. [2 ]
Szymanski, Wiktor [1 ,3 ]
Feringa, Ben L. [1 ]
机构
[1] Univ Groningen, Stratingh Inst Chem, Ctr Syst Chem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands
[2] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Mol Microbiol, Nijenborgh 7, NL-9747 AG Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, Hanze Pl 1, NL-9713 GZ Groningen, Netherlands
[4] Helmholtz Ctr Infect Res, Med Chem, Inhoffenstralle 7, D-38124 Braunschweig, Germany
基金
欧洲研究理事会;
关键词
PHOTODYNAMIC THERAPY; IN-VIVO; AZOBENZENE PHOTOSWITCHES; DIHYDROFOLATE REDUCTASES; ANTIMICROBIAL ACTIVITY; OPTICAL CONTROL; TRIMETHOPRIM; ANTIBIOTICS; RESISTANCE; INHIBITORS;
D O I
10.1021/jacs.7b09281
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The field of photopharmacology aims to introduce smart drugs that, through the incorporation of molecular photoswitches, allow for the remote spatial and temporal control of bioactivity by light. This concept could be particularly beneficial in the treatment of bacterial infections, by reducing the systemic and environmental side effects of antibiotics. A major concern in the realization of such light-responsive drugs is the wavelength of the light that is applied. Studies on the photocontrol of biologically active agents mostly rely on UV light, which is cytotoxic and poorly suited for tissue penetration. In our efforts to develop photoswitchable antibiotics, we introduce here antibacterial agents whose activity can be controlled by visible light, while getting into the therapeutic window. For that purpose, a UV-light-responsive core structure based on diaminopyrimidines with suitable antibacterial properties was identified. Subsequent modification of an azobenzene photoswitch moiety led to structures that allowed us to control their activity against Escherichia coli in both directions with light in the visible region. For the first time, full in situ photocontrol of antibacterial activity in the presence of bacteria was attained with green and violet light. Most remarkably, one of the diaminopyrimidines revealed an at least 8-fold difference in activity before and after irradiation with red light at 652 nm, showcasing the effective "activation" of a biological agent otherwise inactive within the investigated concentration range, and doing so with red light in the therapeutic window.
引用
收藏
页码:17979 / 17986
页数:8
相关论文
共 80 条
  • [1] Resistance to antibiotics: Are we in the post-antibiotic era?
    Alanis, AJ
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2005, 36 (06) : 697 - 705
  • [2] Peripheral neuropathy and Guillain-Barre syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis
    Ali, Ayad K.
    [J]. ANNALS OF EPIDEMIOLOGY, 2014, 24 (04) : 279 - 285
  • [3] TRIMETHOPRIM ACTION AND ITS ANALOGY WITH THYMINE STARVATION
    AMYES, SGB
    SMITH, JT
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1974, 5 (02) : 169 - 178
  • [4] [Anonymous], 2016, ANTIMICROBIAL RESIST
  • [5] [Anonymous], 2015, WORLDW COUNTR SIT AN
  • [6] Controlling Biological Activity with Light: Diarylethene- Containing Cyclic Peptidomimetics
    Babii, Oleg
    Afonin, Sergii
    Berditsch, Marina
    Reisser, Sabine
    Mykhailiuk, Pavel K.
    Kubyshkin, Vladimir S.
    Steinbrecher, Thomas
    Ulrich, Anne S.
    Komarov, Igor V.
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2014, 53 (13) : 3392 - 3395
  • [7] Azobenzene photoswitches for biomolecules
    Beharry, Andrew A.
    Woolley, G. Andrew
    [J]. CHEMICAL SOCIETY REVIEWS, 2011, 40 (08) : 4422 - 4437
  • [8] Visible-Light-Activated Molecular Switches
    Bleger, David
    Hecht, Stefan
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2015, 54 (39) : 11338 - 11349
  • [9] o-Fluoroazobenzenes as Readily Synthesized Photoswitches Offering Nearly Quantitative Two-Way Isomerization with Visible Light
    Bleger, David
    Schwarz, Jutta
    Brouwer, Albert M.
    Hecht, Stefan
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2012, 134 (51) : 20597 - 20600
  • [10] Dihydrofolate reductase inhibitors: developments in antiparasitic chemotherapy
    Bolstad, David B.
    Bolstad, Erin S. D.
    Wright, Dennis L.
    Anderson, Amy C.
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (02) : 143 - 157